Clinical trial
An Open-Label and Double-Blind, Randomized Withdrawal Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Adults With Binge Eating Disorder
NCT06878976 is registered in ClinicalTrials.gov with Axsome Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label and Double-Blind, Randomized Withdrawal Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Adults With Binge Eating Disorder
- Lead sponsor
- Axsome Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Enrolling by invitation
- Start date
- February 20, 2025
- Completion date
- December 31, 2027
- Enrollment
- 236 (estimated)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.